Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

Por Younes, Anas, Romaguera, Jorge, Fanale, Michelle, McLaughlin, Peter, Hagemeister, Frederick, Copeland, Amanda, Neelapu, Sattva, Kwak, Larry, Shah, Jatin, de Castro Faria, Silvana, Hart, Stefan, Wood, Jeanette, Jayaraman, Ramesh, Ethirajulu, Kantharaj, Zhu, Joy
Publicado no J Clin Oncol (2012)

First‐in‐Human, Healthy Volunteers Integrated Protocol of ETC‐206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug

Por Teneggi, Vincenzo, Novotny‐Diermayr, Veronica, Lee, Lay Hoon, Yasin, Maryam, Yeo, Pauline, Ethirajulu, Kantharaj, Gan, Sylvia Bong Hwa, Blanchard, Stephanie E., Nellore, Ranjani, Umrani, Dhananjay N., Gomeni, Roberto, Teck, Darren Lim Wan, Li, Greg, Lu, Qing Shu, Cao, Yang, Matter, Alex
Publicado no Clin Transl Sci (2019)

VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

Por Hart, Stefan, Novotny-Diermayr, Veronica, Goh, Kee Chuan, Williams, Meredith, Tan, Yong Cheng, Ong, Lai Chun, Cheong, Albert, Ng, Bee Kheng, Amalini, Chithra, Madan, Babita, Nagaraj, Harish, Jayaraman, Ramesh, Pasha, Khalid M., Ethirajulu, Kantharaj, Chng, Wee Joo, Mustafa, Nurulhuda, Goh, Boon Cher, Benes, Cyril, McDermott, Ultan, Garnett, Mathew, Dymock, Brian, Wood, Jeanette M.
Publicado em 2012